To investigate whether a gene circuit could specifically treat cancer, we used the NSGEP based on recognition of β-catenin and NF-κB to drive the expression of therapeutic gene in bladder cancer cells specifically. This evidence concerns the gene NFKB1 and urinary bladder carcinoma.